A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6


NCT Number:



Study Status:






The purpose of this study is to test the study drug ALKS 4230 to see how well the drug works on patients with advanced cutaneous melanoma or subjects with advanced muscosal melanoma and have received prior treatment with an anti- programmed death-ligand 1 (anti-PD-[L1]) therapy, and your cancer has spread. This study will explore how well the drug works on your disease and body; also explore potential biomarkers by examining your blood and tissue for genes and proteins that can help identify and/or predict whether a therapy would benefit someone or not.

Are you Eligible? (Inclusion Criteria)

  • Must be 18 years or older at time of consent
  • Must have received prior treatment
  • Must be willing to undergo tumor biopsy if archival tumor tissue is not available

Specialty Area(s)

Skin cancers, Melanoma, Immunotherapy

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032